Literature DB >> 1716596

Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis.

L M Kettel1, A A Murphy, J F Mortola, J H Liu, A Ulmann, S S Yen.   

Abstract

OBJECTIVE: To examine endocrine and clinical responses to long-term administration of RU486 in patients with endometriosis.
DESIGN: Prospective open trial.
SETTING: Faculty practice of the authors. PATIENTS, PARTICIPANTS: Six normally cycling women with endometriosis were recruited.
INTERVENTIONS: Subjects received RU486 100 mg/d for 3 months. MAIN OUTCOME MEASURE(S): Hormonal changes during RU486 were compared with control data obtained in the preceding cycle during the early follicular phase. Clinical responses were determined by patient assessment and second-look laparoscopy.
RESULTS: All women became amenorrheic, and daily urinary levels of ovarian steroid metabolites remained acyclic. Mean luteinizing hormone (LH) (P less than 0.02) and LH pulse amplitude (P less than 0.05) were increased without changes in LH pulse frequency. An antiglucocorticoid effect was demonstrated by an increase in serum cortisol (P less than 0.01) and adrenocorticotropic hormone (P less than 0.05) levels. Treatment resulted in an improvement in pelvic pain in all subjects without significant change in the extent of disease as evaluated by follow-up laparoscopy.
CONCLUSIONS: Daily administration of RU486 results in acyclic ovarian function and improvement in the subjective painful symptoms of endometriosis.

Entities:  

Keywords:  Amenorrhea; Americas; Anovulation; Biology; California; Developed Countries; Diseases; Endocrine System; Endometrial Effects; Endometrium; Genitalia; Genitalia, Female; Gonadotropins; Gonadotropins, Pituitary; Hormone Antagonists; Hormones--changes; Luteinizing Hormone; Menstruation Disorders; Methodological Studies; North America; Northern America; Ovarian Effects; Ovary; Pain--changes; Physiology; Prospective Studies; Research Methodology; Ru-486; Signs And Symptoms; Studies; United States; Urogenital System; Uterus

Mesh:

Substances:

Year:  1991        PMID: 1716596     DOI: 10.1016/s0015-0282(16)54531-2

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  17 in total

Review 1.  Mifepristone. Separating fact from fiction.

Authors:  R C Henshaw; A A Templeton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

2.  Clinical pharmacokinetics of mifepristone.

Authors:  O Heikinheimo
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 3.  Mifepristone for uterine fibroids.

Authors:  Mario Tristan; Leonardo J Orozco; Antonia Steed; Anggie Ramírez-Morera; Peter Stone
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

4.  RU 486 (mifepristone).

Authors:  D A Grimes
Journal:  West J Med       Date:  1992-06

5.  Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.

Authors:  B E Murphy; D Filipini; A M Ghadirian
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

6.  The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells.

Authors:  D X Wen; Y F Xu; D E Mais; M E Goldman; D P McDonnell
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  Antioxidant: a new role for RU-486 and related compounds.

Authors:  S Parthasarathy; A J Morales; A A Murphy
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 8.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

9.  Estradiol and progesterone-induced slowing of gonadotropin-releasing hormone pulse frequency is not reversed by subsequent administration of mifepristone.

Authors:  Christopher R McCartney; Susan K Blank; John C Marshall
Journal:  Endocrine       Date:  2009-07-16       Impact factor: 3.633

Review 10.  A benefit-risk assessment of medical treatment for uterine leiomyomas.

Authors:  Vincenzo De Leo; Giuseppe Morgante; Antonio La Marca; Maria Concetta Musacchio; Massimo Sorace; Chiara Cavicchioli; Felice Petraglia
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.